RUBY News and Press, Rubius Therapeutics Inc. From 05/25/21

Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture PR Newswire CAMBRIDGE, Mass. , May 25, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's in...

CAMBRIDGE, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced...

Rubius just released some early data at the AACR. The data was good, but at $2.37bn market cap, RUBY is overvalued. I will wait for more data and a better price. For further details see: Rubius: Early Positive Data, But Stretched Valuation

CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced ...

Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening PR Newswire CAMBRIDGE, Mass. , May 19, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet'...

CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced ...

Rubius Therapeutics (RUBY): Q1 GAAP EPS of -$0.51 beats by $0.02.Cash, cash equivalents and investments were of $330.7MPress Release For further details see: Rubius Therapeutics EPS beats by $0.02

Positive Initial Data from Phase 1/2 Trial of RTX-240 in Advanced Solid Tumors Demonstrated Single-Agent Activity Providing Initial Validation of the RED PLATFORM ® ; Dose Optimization and Enrollment Continues Continued Progress in Advancing Clinical Programs with Further Enr...

CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the t...

CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announce...